Analyst Reiterates Buy on cbdMD, Maintains $2 Price Target Amid Solid Revenue Momentum and Strategic Expansion

Anthony Vendetti, an analyst from Maxim Group, maintained the Buy rating on cbdMD. The associated price target remains the same with $2.00.

Anthony Vendetti has given his Buy rating due to a combination of factors, including cbdMD’s solid top-line momentum and strategic expansion. He highlights that revenue in F2Q26 exceeded expectations, supported by resilient core product sales and initial contributions from the Bluebird Botanicals acquisition, even as regulatory shifts weighed on certain channels. He also views the new clinical healthcare channel as an important long-term opportunity that could open access to Medicare-related demand once federal frameworks for hemp-derived cannabinoids are more clearly defined.

In addition, Vendetti underscores cbdMD’s balance sheet and liquidity as adequate, noting the company’s modest cash burn, lack of debt, and access to a $10M equity line that can help fund operations and strategic initiatives until expected cashflow breakeven in FY28. He believes integration of Bluebird is progressing, with potential cost synergies and cross-selling benefits ahead. Finally, his unchanged $2 price target reflects a DCF-based valuation and a projected EV/revenue multiple that still sits at a discount to peers, which he sees as attractive given cbdMD’s improving fundamentals and its positioning in a more tightly regulated CBD market.